Show simple item record

dc.contributor.authorColl, Anthony
dc.date.accessioned2018-10-10T10:45:26Z
dc.date.available2018-10-10T10:45:26Z
dc.date.issued2018-07-03
dc.identifier.issn1550-4131
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/283544
dc.description.abstractSafe and effective pharmacological treatments for severe obesity remain scarce. In this issue, Iepsen et al. show that obese patients with pathogenic melanocortin 4 receptor mutations, the most common form of monogenic obesity, lose weight with glucagon-like peptide 1 (GLP-1) receptor agonist therapy.
dc.description.sponsorshipA.P.C. is supported by the Medical Research Council (MRC Metabolic Diseases Unit [MRC_MC_UU_12012/1]).
dc.publisherElsevier
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.titleMonogenic obesity; using drugs to bypass the problem
dc.typeArticle
prism.endingPage2
prism.issueIdentifier1
prism.publicationNameCell Metabolism
prism.startingPage1
prism.volume28
dc.identifier.doi10.17863/CAM.30907
dcterms.dateAccepted2018-06-18
rioxxterms.versionofrecord10.1016/j.cmet.2018.06.015
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.licenseref.startdate2018-06-18
dc.contributor.orcidColl, Anthony [0000-0003-2594-7463]
dc.identifier.eissn1932-7420
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (MC_UU_12012/1)
pubs.funder-project-idMedical Research Council (MC_UU_12012/5)
cam.issuedOnline2018-07-03
rioxxterms.freetoread.startdate2019-07-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record